LabCorp Announces the Availability of Hepatitis C Virus Q80k Polymorphism Screening for the Newly Approved Drug OLYSIO™ (simeprevir) Read more about LabCorp Announces the Availability of Hepatitis C Virus Q80k Polymorphism Screening for the Newly Approved Drug OLYSIO™ (simeprevir)
LabCorp to Offer BRCAssureSM Breast Cancer Mutation Tests Read more about LabCorp to Offer BRCAssureSM Breast Cancer Mutation Tests
LabCorp Announces the Availability of a 4th Generation HIV Assay to Allow the Earlier Detection of Acute HIV Infection Read more about LabCorp Announces the Availability of a 4th Generation HIV Assay to Allow the Earlier Detection of Acute HIV Infection
Garheng Kong Named to LabCorp® Board of Directors Read more about Garheng Kong Named to LabCorp® Board of Directors
LabCorp Announces Proposed Sale of Senior Notes Read more about LabCorp Announces Proposed Sale of Senior Notes
LabCorp Prices $400 Million in 2.50% Senior Notes Due 2018 and $300 Million in 4.00% Senior Notes Due 2023 Read more about LabCorp Prices $400 Million in 2.50% Senior Notes Due 2018 and $300 Million in 4.00% Senior Notes Due 2023
LabCorp to Offer New FDA-Approved Companion Diagnostic for Colorectal Cancer Read more about LabCorp to Offer New FDA-Approved Companion Diagnostic for Colorectal Cancer
Laboratory Corporation of America® Holdings Announces 2013 Third Quarter Results Read more about Laboratory Corporation of America® Holdings Announces 2013 Third Quarter Results
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Read more about Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest Read more about LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
